Findings in life sciences reported from Osaka University
2009 JUL 27 - (NewsRx.com) -- A report, '(18)F-FDG PET for the evaluation of thymic epithelial tumors: Correlation with the World Health Organization classification in addition to dual-time-point imaging,' is newly published data in European Journal of Nuclear Medicine and Molecular Imaging. According to a study from Osaka, Japan, "Our aim was to determine dual-phase (18)F-FDG PET imaging features for various subtypes of thymic epithelial tumors based on the World Health Organization classification. Forty-six patients with histologically verified thymic epithelial tumors [23 with low-risk tumors (4 with type A, 16 with AB, and 3 with B1) and 23 with high-risk tumors (7 with B2, 5 with B3, and 11 with thymic carcinoma] were enrolled in this study." "All patients were injected with (18)F-FDG.; after 1 h, they underwent scanning; after 3 h, 23 patients underwent an additional scanning. The maximum standard uptake value (SUV(max)) and the retention index (RI%) of the lesions were determined. The early and delayed SUV(max) values in the patients with high-risk tumors [early SUV(max) (mean: 6.0) and delayed SUV(max) (mean: 7.4)] were both significantly larger than those in patients with low-risk tumors [early SUV(max) (mean: 3.2) and delayed SUV(max) (mean: 3.4)] (p <0.05). Early SUV(max) values of greater than 7.1 differentiated thymic carcinomas from other types of tumors. For the histological differentiation between high-risk tumors and low-risk tumors, an early SUV(max) value of 4.5 was used as the cutoff. The sensitivity, specificity, and accuracy were 78.3, 91.3, and 84.8%, respectively. High SUV values (early SUV >4.5) suggest the presence of high-risk tumors. A very high SUV value (early SUV >7.1) is useful for the differentiation of thymic carcinomas from other types of tumors," wrote A. Inoue and colleagues, Osaka University. The researchers concluded: "The delayed SUV values were higher than the early SUV values in all types of tumors." Inoue and colleagues published the results of their research in European Journal of Nuclear Medicine and Molecular Imaging ((18)F-FDG PET for the evaluation of thymic epithelial tumors: Correlation with the World Health Organization classification in addition to dual-time-point imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2009;36(8):1219-25). For additional information, contact A. Inoue, Osaka University Graduate School of Medicine, Dept. of Nuclear Medicine and Tracer Kinetics, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. The publisher of the European Journal of Nuclear Medicine and Molecular Imaging can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA. Keywords: Japan, Osaka, Life Sciences, Thymoma, Thymic Cancer, Thymic Carcinoma, Oncology, Nuclear Medicine, Epidemiology. This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2009, Clinical Oncology Week via NewsRx.com.
|
